📰 Priority Review News
Page 81 - Priority Review News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Priority Review. Real-time updates on events, politics, business and more.
December 16, 2022
/PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Adstiladrin (nadofaragene firadenovec-vncg), a non-replicating (cannot multiply in human...
December 16, 2022
/PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Adstiladrin (nadofaragene firadenovec-vncg), a non-replicating (cannot multiply in human...
December 15, 2022
New England Journal of Medicine Publishes Phase 3 Data on B-VEC in Patients with Dystrophic Epidermolysis Bullosa - read this article along with other careers information, tips and advice on BioSpace
December 15, 2022
AstraZeneca granted PDUFA extension to allow further time for a full review on Lynparza
December 14, 2022
The FDA has accepted for Priority Review the sNDA for Narcan (naloxone HCl) Nasal Spray as an OTC emergency treatment.
December 14, 2022
The RSVpreF vaccine candidate consists of 2 prefusion F proteins selected to optimize protection against RSV A and B.
December 14, 2022
PITTSBURGH, Dec. 14, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases, announced today that dat...
December 13, 2022
/PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB),...
December 12, 2022
The FDA, which started 2022, on a slow note, has so far approved 30 novel drugs, compared to 47 that were approved during the same period last year. Now, lets take a look at the biotech stocks facing FDA decision in December.